Do decision makers really need health economic data?

Value in Health

Volumn 6, Issue 4, 2003, Pages 404-406

  Mather, Dell ^a  

^a Prime Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; EDITORIAL; HEALTH CARE COST; HEALTH ECONOMICS; MANAGED CARE ORGANIZATION; MEDICAL RESEARCH; PHARMACEUTICAL CARE; PHARMACY BENEFIT MANAGER; PRIORITY JOURNAL;

EID: 0041707975     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2003.64002.x     Document Type: Editorial

References (5)

1. Drummond M, Brown R, Fendrick MA, et al. Use of pharmacoeconomics information - Report of the ISPOR Task Force on use of pharmacoeconomics/health economic information in health-care decision making. Value Health 2003;6:407-16.
2. Format for formulary submissions. Version 2.0. Alexandria (VA): AMCP, 2002 Oct.
3. Harris G. Drug Sales Growth Slowed, but Still Rose 12% in 2002. The Wall Street Journal. 2003 Feb 21.
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-97.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.